RMC No. 56-2022 updates the VAT-exempt medicines list for hypertension and COVID-19 treatment under the CREATE Act, requiring item-level VAT review.

Pharmacies, hospitals, distributors, importers, clinics, and businesses selling or purchasing medicines for hypertension and COVID-19 treatment should immediately review their VAT treatment because RMC No. 56-2022 updates the List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE Act. The key consequence is practical and immediate: medicines newly included in the VAT-exempt list should no longer be treated as ordinary VATable sales, while corrected hypertension medicine entries must be matched carefully against product records, invoices, point-of-sale systems, and accounting classifications.

What RMC No. 56-2022 Changed

RMC No. 56-2022, issued on April 27, 2022, publishes the March 16, 2022 endorsement from the Food and Drug Administration of the Department of Health updating the List of VAT-Exempt Medicines under RA No. 11534, also known as the CREATE Act. The update covers medicines for hypertension and COVID-19 treatment. Certain medicines for hypertension and COVID-19 treatment were included in the list, while corrections were made for several hypertension medicines.

For businesses, the operational issue is not merely whether a product is medical in nature. The relevant question is whether the specific medicine is covered by the updated VAT-exempt medicines list as endorsed by the FDA and published through the BIR issuance. Product classification must therefore be checked at the medicine level, not merely at the category level. A business cannot assume that all medicines related to hypertension or COVID-19 treatment automatically receive the same tax treatment unless the item is covered by the updated list.

The issuance is important because VAT treatment affects pricing, invoicing, accounting entries, tax returns, customer billing, and supplier coordination. A medicine treated as VAT-exempt should not be billed with VAT as though it were an ordinary VATable sale. Conversely, a medicine not covered by the updated VAT-exempt list should not be reclassified without support. For CFOs, corporate accountants, and pharmacy operators, RMC No. 56-2022 should trigger a product master file review and tax mapping exercise.

Who Is Most Affected

The taxpayers most affected are pharmacies, drugstores, hospitals, clinics, healthcare providers, pharmaceutical distributors, medicine importers, wholesalers, and retail businesses that sell medicines for hypertension and COVID-19 treatment. The issuance also affects corporate buyers and institutional procurement teams that purchase these medicines for employee health programs, clinic inventories, or healthcare operations, because VAT treatment can affect billing, reimbursement, and documentation.

Accounting teams should pay particular attention if their systems use automated VAT tagging. If a product code, SKU, or medicine description remains tagged as VATable after inclusion in the VAT-exempt list, the business may issue invoices or receipts that do not reflect the updated treatment. If corrections were made to hypertension medicine entries, the business should also confirm whether previous descriptions, names, or classifications in its internal records match the corrected list.

This is especially relevant for businesses with multiple branches or centralized inventory systems. A head office may update its tax matrix, but branch-level point-of-sale systems, warehouse records, and sales invoices may still reflect outdated VAT treatment. The search terms that affected taxpayers are likely to use include RMC No. 56-2022 VAT-exempt medicines, CREATE Act VAT exemption medicines, FDA VAT-exempt hypertension medicines, COVID-19 treatment medicines VAT exemption, and BIR VAT-exempt medicine list Philippines.

Key Compliance Requirements and Timing

The relevant issuance date is April 27, 2022. RMC No. 56-2022 publishes the FDA endorsement dated March 16, 2022. The document does not state a separate rate, threshold, or special transition period. The compliance focus is therefore on correctly identifying the included and corrected medicines and applying the proper VAT treatment in business records and tax reporting from the time the updated list is published and implemented.

Businesses should verify whether the medicines they sell, distribute, procure, or reimburse are included in the updated list. For newly included medicines for hypertension and COVID-19 treatment, the VAT treatment must be aligned with their VAT-exempt status. For hypertension medicines with corrected entries, the business should reconcile the corrected information against its inventory master list, supplier descriptions, purchase invoices, sales invoices, and tax codes.

The compliance requirement is documentation-driven. Taxpayers should keep a clear internal record showing why a particular product was treated as VAT-exempt. This may include the product description used in the updated list, the internal SKU, the supplier invoice description, and the tax code applied in the accounting system. When the BIR reviews sales, purchases, or VAT returns, the business should be able to explain the basis for the VAT-exempt treatment without relying on informal assumptions.

Penalties and Tax Risk for Non-Compliance

RMC No. 56-2022 does not create a special penalty provision in the text summarized by the issuance. However, incorrect VAT treatment can still create tax exposure under general tax rules. If a VAT-exempt medicine is wrongly billed as VATable, the business may face customer disputes, accounting corrections, and possible issues in VAT reporting. If a medicine is wrongly treated as VAT-exempt without being covered by the updated list, the business may face deficiency VAT exposure, surcharges, interest, compromise penalties, and documentary issues during audit.

The larger risk for regulated healthcare and pharmaceutical businesses is inconsistency. A taxpayer that treats the same medicine differently across branches, invoices, or reporting periods may invite questions during BIR examination. The correction of several hypertension medicine entries makes accuracy even more important. Businesses should avoid broad category-based tax coding and instead maintain item-level support for VAT exemption.

Practical Steps for Businesses

First, identify all medicines in the company inventory, sales, procurement, or reimbursement system that relate to hypertension and COVID-19 treatment. Second, compare those medicines against the updated VAT-exempt medicines list published through RMC No. 56-2022. Third, update product tax codes in the accounting system, point-of-sale system, enterprise resource planning system, and invoice templates. Fourth, instruct accounting, treasury, procurement, and branch personnel on the revised treatment so that sales and purchase documentation remain consistent.

Fifth, review prior invoices issued around the implementation period and determine whether any correction, credit memo, adjustment, or internal reconciliation is necessary. Sixth, maintain an audit file showing the basis for the VAT-exempt treatment. This is particularly important for companies with large inventories of medicines, recurring institutional buyers, or significant healthcare-related procurement.

For corporate accountants and tax managers, the most important immediate action is to prevent mismatches between legal tax treatment and system-generated invoices. The issuance affects a narrow but commercially important group of products: medicines for hypertension and COVID-19 treatment, including corrected hypertension medicine entries. A system update made late or applied inconsistently can create preventable VAT reporting problems.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco advises businesses on BIR compliance, VAT classification, tax documentation, healthcare-related commercial transactions, and audit readiness. For pharmacies, hospitals, distributors, importers, and corporate buyers affected by RMC No. 56-2022, our team can help review product classifications, assess VAT exposure, prepare internal compliance guidance, and coordinate tax documentation for audit defense.

If your business sells, distributes, imports, reimburses, or procures medicines for hypertension or COVID-19 treatment, this is the time to confirm whether your invoices, tax codes, and accounting records reflect the updated VAT-exempt medicines list. For assistance with BIR compliance and Philippine tax advisory, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.

Leave a Comment

Your email address will not be published. Required fields are marked *